Dinah Sah

Dinah Sah, Ph.D.
is a Scientific Advisor to Vida Ventures.
She most recently served as Chief Scientific Officer at Voyager Therapeutics, a biotech company that she helped launch in 2014, focused on the discovery and development of AAV gene therapy for the treatment of severe neurological diseases.
Prior to Voyager Therapeutics, Dinah was Vice President of Research at Alnylam Pharmaceuticals, and led research efforts from 2005-2012 to develop a new class of drugs based on RNA interference.
She previously served at Biogen from 1999-2005 and Signal Pharmaceuticals from 1993-1999 where she provided neuroscience research leadership focused on protein therapeutics and neural stem cells, respectively.
Dinah’s accomplishments include leadership of multiple programs from early research through Phase 1 clinical trials, and the discovery of novel therapeutic targets and drug candidates that advanced into clinical development.
Her leadership of drug discovery and development programs based on RNAi therapeutics resulted in the landmark demonstration of human proof-of-mechanism for this novel class of drugs in TTR amyloidosis patients which led to the approval of ONPATTRO® (patisiran).
Dinah obtained a B.S.
in Biology from the Massachusetts Institute of Technology and a Ph.D.
in Neurobiology from Harvard University.
She serves as a member of the scientific advisory boards of Voyager Therapeutics